{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:00:16Z","timestamp":1790204416896,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T00:00:00Z","timestamp":1311724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s11912-011-0186-8","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T02:11:20Z","timestamp":1311646280000},"page":"416-426","source":"Crossref","is-referenced-by-count":23,"title":["Newly Emerging Therapies Targeting Viral-Related Lymphomas"],"prefix":"10.1007","volume":"13","author":[{"given":"Juan Carlos","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,27]]},"reference":[{"key":"186_CR1","doi-asserted-by":"crossref","unstructured":"Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 118(12):3030.","DOI":"10.1002\/ijc.21731"},{"key":"186_CR2","volume-title":"Infections with Epstein-Barr virus and human herpes viruses, vol. 70","author":"IARC monographs on the evaluation of carcinogenic risks to humans","year":"1997","unstructured":"IARC monographs on the evaluation of carcinogenic risks to humans. Infections with Epstein-Barr virus and human herpes viruses, vol. 70. Lyon: IARC; 1997."},{"key":"186_CR3","doi-asserted-by":"crossref","unstructured":"\u2022 Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;Feb 7. This publication describes the inclusion of rare EBV-related lymphoproliferative diseases and diffuse large B-cell lymphoma variants as separate disease entities.","DOI":"10.1182\/blood-2011-01-293050"},{"issue":"6","key":"186_CR4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","volume":"113","author":"E Cesarman","year":"2009","unstructured":"\u2022\u2022 Cesarman E, Spina M, Gloghini A, et al. HIV-associated lymphomas and gamma herpesviruses. Blood 2009;113(6):1213\u201324. At the time of this publication, this is the most complete and up-to-date clinical, pathologic, and biological review of EBV-related and HHV-8\u2013related lymphomas occurring in HIV patients.","journal-title":"Blood"},{"issue":"30","key":"186_CR5","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","volume":"27","author":"A Chadburn","year":"2009","unstructured":"\u2022 Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009;27(30):5039\u201348. This report accurately describes the incidence of EBV and histologic or immunophenotypic characteristics of HIV-associated diffuse large B-cell lymphoma variants.","journal-title":"J Clin Oncol"},{"issue":"30","key":"186_CR6","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","volume":"23","author":"IM Ghobrial","year":"2005","unstructured":"Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23(30):7574\u201382.","journal-title":"J Clin Oncol"},{"key":"186_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000478-200003000-00006","volume":"24","author":"BP Nelson","year":"2000","unstructured":"Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24:375\u201385.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"186_CR8","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77(12):7415\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"186_CR9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","volume":"79","author":"M Yoshida","year":"1982","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79(6):2031\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"186_CR10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nrc2961","volume":"10","author":"PS Moore","year":"2010","unstructured":"\u2022\u2022 Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010;10(12):878\u201389. This publication is a thorough review of the role of oncogenic viruses in tumorigenesis and immune evasion.","journal-title":"Nat Rev Cancer"},{"key":"186_CR11","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2010 Nov 29. This publication is the most up-to-date comprehensive review about the pathogenesis of HTLV-I and the molecular steps leading to transformation and adult T-cell leukemia.","DOI":"10.1038\/onc.2010.537"},{"issue":"39","key":"186_CR12","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/sj.onc.1208981","volume":"24","author":"M Yoshida","year":"2005","unstructured":"Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene. 2005;24(39):5931\u20137.","journal-title":"Oncogene"},{"issue":"39","key":"186_CR13","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1038\/sj.onc.1208969","volume":"24","author":"SC Sun","year":"2005","unstructured":"Sun SC, Yamaoka S. Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene. 2005;24(39):5952\u201364.","journal-title":"Oncogene"},{"issue":"6","key":"186_CR14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tim.2010.04.001","volume":"18","author":"DE Oliveira de","year":"2010","unstructured":"de Oliveira DE, Ballon G, Cesarman E. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol. 2010;18(6):248\u201357.","journal-title":"Trends Microbiol"},{"key":"186_CR15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M Karin","year":"2002","unstructured":"Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301\u201310.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"186_CR16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925\u201335.","journal-title":"Blood"},{"issue":"5","key":"186_CR17","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.4049\/jimmunol.177.5.3283","volume":"177","author":"AL Snow","year":"2006","unstructured":"Snow AL, Lambert SL, Natkunam Y, et al. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol. 2006;177(5):3283\u201393.","journal-title":"J Immunol"},{"issue":"4","key":"186_CR18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/JVI.78.4.1918-1927.2004","volume":"78","author":"CC Tomlinson","year":"2004","unstructured":"Tomlinson CC, Damania B. The K1 protein of Kaposi\u2019s sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004;78(4):1918\u201327.","journal-title":"J Virol"},{"issue":"7","key":"186_CR19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1084\/jem.20031467","volume":"199","author":"I Guasparri","year":"2004","unstructured":"Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199(7):993\u20131003.","journal-title":"J Exp Med"},{"issue":"15","key":"186_CR20","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1128\/JVI.77.15.8532-8540.2003","volume":"77","author":"HJ Brown","year":"2003","unstructured":"Brown HJ, Song MJ, Deng H, et al. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol. 2003;77(15):8532\u201340.","journal-title":"J Virol"},{"issue":"1","key":"186_CR21","first-page":"93","volume":"19","author":"JS Seo","year":"2008","unstructured":"Seo JS, Cho NY, Kim HR, et al. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. Oncol Rep. 2008;19(1):93\u20138.","journal-title":"Oncol Rep"},{"issue":"10","key":"186_CR22","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","volume":"126","author":"KF Hui","year":"2010","unstructured":"Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer. 2010;126(10):2479\u201389.","journal-title":"Int J Cancer"},{"issue":"47","key":"186_CR23","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1038\/sj.onc.1205701","volume":"21","author":"T Ego","year":"2002","unstructured":"Ego T, Ariumi Y, Shimotohno K. The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. Oncogene. 2002;21(47):7241\u20136.","journal-title":"Oncogene"},{"issue":"2","key":"186_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2008.0191","volume":"25","author":"NM Archin","year":"2009","unstructured":"Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009;25(2):207\u201312.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"186_CR25","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1182\/blood.V87.12.5279.bloodjournal87125279","volume":"87","author":"I Araujo","year":"1996","unstructured":"Araujo I, Foss HD, Bittencourt A, et al. Expression of Epstein-Barr virus-gene products in Burkitt\u2019s lymphoma in Northeast Brazil. Blood. 1996;87(12):5279\u201386.","journal-title":"Blood"},{"issue":"4","key":"186_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","volume":"70","author":"SL Glaser","year":"1997","unstructured":"Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375\u201382.","journal-title":"Int J Cancer"},{"key":"186_CR27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0092-8674(85)90256-9","volume":"43","author":"D Wang","year":"1985","unstructured":"Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalised lymphocytes transforms established rodent cells. Cell. 1985;43:831\u201340.","journal-title":"Cell"},{"key":"186_CR28","first-page":"549","volume":"10","author":"DS Huen","year":"1995","unstructured":"Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein\u2013Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-\u03baB and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain. Oncogene. 1995;10:549\u201360.","journal-title":"Oncogene"},{"issue":"3","key":"186_CR29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4049\/jimmunol.155.3.1047","volume":"155","author":"L Arvanitakis","year":"1995","unstructured":"Arvanitakis L, Yaseen N, Sharma S. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol. 1995;155(3):1047\u201356.","journal-title":"J Immunol"},{"issue":"1408","key":"186_CR30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1098\/rstb.2000.0777","volume":"356","author":"PS Moore","year":"2001","unstructured":"Moore PS, Chang Y. Molecular virology of Kaposi\u2019s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci. 2001;356(1408):499\u2013516.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"9","key":"186_CR31","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/j.1460-2075.1987.tb02568.x","volume":"6","author":"M Rowe","year":"1987","unstructured":"Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt\u2019s lymphoma cells. EMBO J. 1987;6(9):2743\u201351.","journal-title":"EMBO J"},{"issue":"16","key":"186_CR32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJM198910193211604","volume":"321","author":"L Young","year":"1989","unstructured":"Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321(16):1080\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"186_CR33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.177.2.339","volume":"177","author":"EM Deacon","year":"1993","unstructured":"Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin\u2019s disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177(2):339\u201349.","journal-title":"J Exp Med"},{"key":"186_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell RG, Wilson JB, Anderson SJ, et al. Epstein\u2013Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9:405\u201311.","journal-title":"Immunity"},{"issue":"19","key":"186_CR35","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1093\/nar\/21.19.4483","volume":"21","author":"TV Sharp","year":"1993","unstructured":"Sharp TV, Schwemmle M, Jeffrey I, et al. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res. 1993;21(19):4483.","journal-title":"Nucleic Acids Res"},{"key":"186_CR36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","volume":"68","author":"T Xia","year":"2008","unstructured":"Xia T, O\u2019Hara A, Araujo I, et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 2008;68:1436\u201342.","journal-title":"Cancer Res"},{"issue":"7","key":"186_CR37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.7150\/ijbs.6.730","volume":"6","author":"ZM Zheng","year":"2010","unstructured":"Zheng ZM. Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci. 2010;6(7):730\u201355.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"186_CR38","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1128\/JVI.72.7.5433-5440.1998","volume":"72","author":"M Li","year":"1998","unstructured":"Li M, Lee H, Guo J, Neipel F, et al. Kaposi\u2019s sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol. 1998;72(7):5433\u201340.","journal-title":"J Virol"},{"key":"186_CR39","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1128\/JVI.73.3.2232-2242.1999","volume":"73","author":"R Sun","year":"1999","unstructured":"Sun R et al. Kinetics of Kaposi\u2019s sarcoma-associated herpesvirus gene expression. J Virol. 1999;73:2232\u201342.","journal-title":"J Virol"},{"issue":"5","key":"186_CR40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","volume":"117","author":"EP Simard","year":"2011","unstructured":"\u2022 Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011;117(5):1089\u201396. This review describes the most recent trends in HIV-associated malignancies during the HAART era.","journal-title":"Cancer"},{"key":"186_CR41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-143-4-200508160-00007","volume":"143","author":"M Bower","year":"2005","unstructured":"Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143:265\u201373.","journal-title":"Ann Intern Med"},{"issue":"2","key":"186_CR42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0145-2126(01)00113-8","volume":"26","author":"A Tulpule","year":"2002","unstructured":"Tulpule A, Sherrod A, Dharmapala D, et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002;26(2):121\u20137.","journal-title":"Leuk Res"},{"issue":"12","key":"186_CR43","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","volume":"101","author":"RF Little","year":"2003","unstructured":"Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653\u20139.","journal-title":"Blood"},{"issue":"5","key":"186_CR44","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","volume":"105","author":"M Spina","year":"2005","unstructured":"Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891\u20137.","journal-title":"Blood"},{"key":"186_CR45","doi-asserted-by":"crossref","unstructured":"Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas. Blood. 1997;89:601\u20139","DOI":"10.1182\/blood.V89.2.601"},{"issue":"6769","key":"186_CR46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"key":"186_CR47","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010 Feb 3.","DOI":"10.1182\/blood-2009-11-253039"},{"key":"186_CR48","doi-asserted-by":"crossref","unstructured":"Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated, B-cell non-Hodgkin\u2019s lymphoma. Blood. 2009 Dec 29.","DOI":"10.1182\/blood-2009-08-231613"},{"key":"186_CR49","unstructured":"Barta SK, Lee JY, Sparano JA, et al. Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin\u2019s lymphoma (Abstract\/Oral presentation 011). Presented at the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies."},{"issue":"10","key":"186_CR50","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","volume":"107","author":"N Mounier","year":"2006","unstructured":"Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107(10):3832\u201340.","journal-title":"Blood"},{"issue":"5","key":"186_CR51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/CCO.0b013e32833d7dbe","volume":"22","author":"A Noy","year":"2010","unstructured":"Noy A. Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol. 2010;22(5):443\u20138.","journal-title":"Curr Opin Oncol"},{"key":"186_CR52","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413\u201320.","journal-title":"Blood"},{"issue":"5","key":"186_CR53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1309\/AJCPJH6KEUSECQLU","volume":"134","author":"D Hansra","year":"2010","unstructured":"Hansra D, Montague N, Stefanovic A, et al. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol. 2010;134(5):710\u20139.","journal-title":"Am J Clin Pathol"},{"key":"186_CR54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJM199808133390705","volume":"339","author":"D Jones","year":"1998","unstructured":"Jones D, Ballestas ME, Kaye KM, et al. Primary-effusion lymphoma and Kaposi\u2019s sarcoma in a cardiactransplant recipient. N Engl J Med. 1998;339:444\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"186_CR55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1349-7006.2010.01820.x","volume":"102","author":"K Tajima","year":"2011","unstructured":"Tajima K. Epidemiology, clinical features and prevention of HTLV-I infection. Cancer Sci. 2011;102(2):295\u2013301. ISBT Science Series, Volume 4, Issue n2, pages 352\u2013356, November 2009.","journal-title":"Cancer Sci"},{"issue":"3","key":"186_CR56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79(3):428\u201337.","journal-title":"Br J Haematol"},{"issue":"34","key":"186_CR57","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Japan Clinical Oncology Group Study JCOG9801, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458\u201364.","journal-title":"J Clin Oncol"},{"issue":"45","key":"186_CR58","doi-asserted-by":"crossref","first-page":"31453","DOI":"10.1074\/jbc.M109.046235","volume":"284","author":"S Mansouri","year":"2009","unstructured":"Mansouri S, Choudhary G, Sarzala PM, et al. Suppression of human T-cell leukemia virus I gene expression by pokeweed antiviral protein. J Biol Chem. 2009;284(45):31453\u201362.","journal-title":"J Biol Chem"},{"issue":"27","key":"186_CR59","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"\u2022 Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177\u201383. This is the first meta-analysis demonstrating the efficacy of AZT and IFN\u03b1 therapy in adult T-cell leukemia-lymphoma.","journal-title":"J Clin Oncol"},{"issue":"3","key":"186_CR60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"\u2022 Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453\u20139. This publication describes the first international recommendation guidelines for the clinical management of adult T-cell leukemia-lymphoma.","journal-title":"J Clin Oncol"},{"issue":"23","key":"186_CR61","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1200\/JCO.2010.29.7242","volume":"28","author":"R Suzuki","year":"2010","unstructured":"Suzuki R. Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(23):e404\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"186_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-006-9060-0","volume":"27","author":"TA Waldmann","year":"2007","unstructured":"Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007;27(1):1\u201318.","journal-title":"J Clin Immunol"},{"issue":"39","key":"186_CR63","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1038\/sj.onc.1208974","volume":"24","author":"MD Lairmore","year":"2005","unstructured":"Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 2005;24(39):6005\u201315.","journal-title":"Oncogene"},{"key":"186_CR64","first-page":"2360","volume":"93","author":"N Mori","year":"1999","unstructured":"Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999;93:2360\u20138.","journal-title":"Blood"},{"key":"186_CR65","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2006-06-026997","volume":"109","author":"JC Ramos","year":"2007","unstructured":"Ramos JC, Ruiz P, Ratner L, et al. IRF-4 and c-Rel expression in antiviral therapy resistant adult T-cell leukemia\/lymphoma. Blood. 2007;109:3060\u20138.","journal-title":"Blood"},{"key":"186_CR66","doi-asserted-by":"crossref","unstructured":"Ramos JC, Diaz LM, Manrique M, et al. Zidovudine blocks NF-\u03baB activity in vivo in adult t-cell leukemia blood (American Society of Hematology Annual Meeting Abstracts), Nov 2008; 112:2524. Presented at the 2008 American Society of Hematology Annual Conference.","DOI":"10.1182\/blood.V112.11.2524.2524"},{"issue":"17","key":"186_CR67","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2008-08-175901","volume":"113","author":"CA Pise-Masison","year":"2009","unstructured":"Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009;113(17):4016\u201326.","journal-title":"Blood"},{"issue":"7","key":"186_CR68","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3109\/10428191003728628","volume":"51","author":"AA Alizadeh","year":"2010","unstructured":"Alizadeh AA, Bohen SP, Lossos C, et al. Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma. 2010;51(7):1200\u201316.","journal-title":"Leuk Lymphoma"},{"key":"186_CR69","unstructured":"Xu S, Lima R, J. Ramos J, et al. New genomic profile signatures revealed in Western World adult T-cell leukemia\/lymphoma patients by 244\u00a0K array CGH (Abstract\/Presentation; Program Number 437). Presented at the American Society of Human Genetics 2010 Annual Meeting."},{"issue":"12","key":"186_CR70","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood.V97.12.3875","volume":"97","author":"K Tsukasaki","year":"2001","unstructured":"Tsukasaki K, Krebs J, Nagai K, et al. Comparative genomic hybridization analysis in adult T-cell leukemia\/lymphoma: correlation with clinical course. Blood. 2001;97(12):3875\u201381.","journal-title":"Blood"},{"issue":"11","key":"186_CR71","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2005-09-3801","volume":"107","author":"A Oshiro","year":"2006","unstructured":"Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia\/lymphoma. Blood. 2006;107(11):4500\u20137.","journal-title":"Blood"},{"issue":"6","key":"186_CR72","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.trstmh.2008.02.009","volume":"102","author":"PB Hesseling","year":"2008","unstructured":"Hesseling PB, Molyneux E, Kamiza S, et al. Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt\u2019s lymphoma. Trans R Soc Trop Med Hyg. 2008;102(6):602\u20137.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"186_CR73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","volume":"5","author":"AM Evens","year":"2008","unstructured":"Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008;5(9):543\u201356.","journal-title":"Nat Clin Pract Oncol"},{"issue":"11","key":"186_CR74","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3109\/10428190903186502","volume":"50","author":"H Kohrt","year":"2009","unstructured":"Kohrt H, Advani R. Extranodal natural killer\/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma. 2009;50(11):1773\u201384.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"186_CR75","first-page":"393","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60(6):393\u2013408.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"186_CR76","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"106","author":"LD Kaplan","year":"2005","unstructured":"Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538\u201343.","journal-title":"Blood"},{"issue":"4","key":"186_CR77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","volume":"140","author":"JM Ribera","year":"2008","unstructured":"Ribera JM, Oriol A, Morgades M, et al. PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140(4):411\u20139.","journal-title":"Br J Haematol"},{"issue":"6","key":"186_CR78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11912-010-0132-1","volume":"12","author":"AM Evens","year":"2010","unstructured":"Evens AM, Roy R, Sterrenberg D, et al. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12(6):383\u201394.","journal-title":"Curr Oncol Rep"},{"issue":"19","key":"186_CR79","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"186_CR80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","volume":"147","author":"M Dickinson","year":"2009","unstructured":"Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009;147(1):97\u2013101.","journal-title":"Br J Haematol"},{"issue":"18","key":"186_CR81","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","volume":"81","author":"P Zou","year":"2007","unstructured":"Zou P, Kawada J, Pesnicak L, et al. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007;81(18):10029\u201336.","journal-title":"J Virol"},{"issue":"10","key":"186_CR82","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2403460","volume":"18","author":"J An","year":"2004","unstructured":"An J, Sun Y, Fisher M, et al. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004;18(10):1699\u2013704.","journal-title":"Leukemia"},{"issue":"15","key":"186_CR83","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1200\/JCO.2006.09.8293","volume":"25","author":"HE Carraway","year":"2007","unstructured":"Carraway HE, Gore SD. Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol. 2007;25(15):1955\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"186_CR84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14728222.9.4.809","volume":"9","author":"RR Rosato","year":"2005","unstructured":"Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets. 2005;9(4):809\u201324.","journal-title":"Expert Opin Ther Targets"},{"issue":"9485","key":"186_CR85","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366(9485):549\u201355.","journal-title":"Lancet"},{"issue":"4","key":"186_CR86","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2005-09-008086","volume":"108","author":"B Sanchez-Gonzalez","year":"2006","unstructured":"Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006;108(4):1174\u201382.","journal-title":"Blood"},{"issue":"5","key":"186_CR87","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-08-1587","volume":"15","author":"K Shiozawa","year":"2009","unstructured":"Shiozawa K, Nakanishi T, Tan M, et al. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res. 2009;15(5):1698\u2013707.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"186_CR88","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/AAC.42.11.2923","volume":"42","author":"EA Gustafson","year":"1998","unstructured":"Gustafson EA, Chillemi AC, Sage DR, et al. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 1998;42(11):2923\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"186_CR89","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1128\/AAC.45.7.2082-2091.2001","volume":"45","author":"SM Moore","year":"2001","unstructured":"Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother. 2001;45(7):2082\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"186_CR90","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine SP, Hermine O, Small T, et al. A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571\u20138.","journal-title":"Blood"},{"key":"186_CR91","first-page":"965","volume":"63","author":"S Roychowdhury","year":"2003","unstructured":"Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003;63:965\u201371.","journal-title":"Cancer Res"},{"issue":"8","key":"186_CR92","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/088922299310809","volume":"15","author":"L Raez","year":"1999","unstructured":"Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15(8):713\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"186_CR93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2004-09-3748","volume":"106","author":"M Kurokawa","year":"2005","unstructured":"Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106(1):235\u201340.","journal-title":"Blood"},{"issue":"4","key":"186_CR94","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","volume":"78","author":"WH Feng","year":"2004","unstructured":"Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78(4):1893\u2013902.","journal-title":"J Virol"},{"key":"186_CR95","doi-asserted-by":"crossref","unstructured":"Feng WH, Cohen JI, Fischer S, Li L, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):","DOI":"10.1093\/jnci\/djh313"},{"issue":"2","key":"186_CR96","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V89.2.419","volume":"89","author":"P Tosi","year":"1997","unstructured":"Tosi P, Gherlinzoni F, Mazza P, et al. 3\u2032-Azido 3\u2032-deoxythymidine+methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin\u2019s lymphomas. Blood. 1997;89(2):419\u201325.","journal-title":"Blood"},{"key":"186_CR97","unstructured":"Bayraktar D, Bernal E, Cabral L, et al. The use of high-dose azidothymidine in combination with chemotherapy upfront is an effective treatment approach for gamma-herpes virus-related non-Hodgkin\u2019s lymphomas (Abstract\/Poster 032). Presented at the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies."},{"key":"186_CR98","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood.V96.7.2537","volume":"96","author":"SA Keller","year":"2000","unstructured":"Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96:2537\u201342.","journal-title":"Blood"},{"issue":"5","key":"186_CR99","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3816\/CLM.2008.n.042","volume":"8","author":"T Siddiqi","year":"2008","unstructured":"Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008;8(5):300\u20134.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"29","key":"186_CR100","doi-asserted-by":"crossref","first-page":"13069","DOI":"10.1073\/pnas.1002985107","volume":"107","author":"KA Sarosiek","year":"2010","unstructured":"\u2022\u2022 Sarosiek KA, Cavallin LE, Bhatt S, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA. 2010;107(29):13069\u201374. In this study we demonstrate proof of concept of targeting viral latency using a novel commercially available biological agent for primary effusion lymphoma, an aggressive \u03b3-herpesvirus malignancy, using an animal model.","journal-title":"Proc Natl Acad Sci USA"},{"key":"186_CR101","doi-asserted-by":"crossref","unstructured":"Seegulam ME, Ratner L. Integrase inhibitors effective against human t-cell leukemia virus type 1. Antimicrob Agents Chemother. 2011 Feb 22.","DOI":"10.1186\/1742-4690-8-S1-A34"},{"issue":"10","key":"186_CR102","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2007-04-085076","volume":"110","author":"A Lezin","year":"2007","unstructured":"Lezin A, Gillet N, Olindo S, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy\/tropical spastic paraparesis patients. Blood. 2007;110(10):3722\u20138.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-011-0186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-011-0186-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-011-0186-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T02:38:37Z","timestamp":1712630317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-011-0186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1007\/s11912-011-0186-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}